[Possible mechanism of action of drugs in the basic therapy of rheumatoid arthritis: effect on platelet aggregation]. 1984

A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo

As it is known that platelets play an important role in arising and maintaining the inflammation, the authors have studied "in vitro", the effect on platelet aggregation of three drugs (Sodium Aurothiomalate, Auranofin and Penicillamine) used in basic therapy of Rheumatoid Arthritis (RA). The drugs are used in different concentrations and at different times of preincubation. The study was based on the principle of Born and using the Coagg-Salus aggregometer. The platelet aggregation was induced by ADP 2.5 microM. The authors have demonstrated that the above-named drugs inhibit the platelet aggregation induced by ADP in different percentile, according to the concentrations adopted and the time of preincubation with platelets rich plasma. This study seems particularly interesting because it can offer a possible interpretation on the mechanism of action of basic therapy in RA.

UI MeSH Term Description Entries
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006051 Aurothioglucose A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals. Gold Thioglucose,Aureotan,Auromyose,Aurothioglucose, Sodium Salt, beta-D Isomer,Aurothioglucose, beta-D Isomer,Gold-50,Solganal,Solganal B Oleosum,Solganol,Thioglucosoaurate,Aurothioglucose, beta D Isomer,B Oleosum, Solganal,Gold 50,Gold50,Oleosum, Solganal B,Thioglucose, Gold,beta-D Isomer Aurothioglucose
D006052 Gold Sodium Thiomalate A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. Aurothiomalate,Gold Thiomalate,Sodium Gold Thiomalate,Aurolate,Gold Disodium Thiomalate, Monohydrate,Gold Thiomalic Acid,Mercaptobutanedioic Acid Monogold(1+) Sodium Salt,Miocrin,Miocrisin,Monogold (1+) Disodium Thiomalate,Myochrysine,Myocrisin,Myocrysine,Sodium Aurothiomalate,Sodium Thiomalatoaurate,Tauredon,Aurothiomalate, Sodium,Gold Thiomalate, Sodium,Sodium Thiomalate, Gold,Thiomalate, Gold,Thiomalatoaurate, Sodium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D001310 Auranofin An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162

Related Publications

A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
July 1985, Arthritis and rheumatism,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
March 1977, Ryumachi. [Rheumatism],
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
May 1990, Comprehensive therapy,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
January 1999, Comprehensive therapy,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
January 1994, Terapevticheskii arkhiv,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
January 1988, Terapevticheskii arkhiv,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
October 1981, Medizinische Klinik,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
July 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
January 1975, Series haematologica (1968),
A Fioravanti, and V Lolatte, and N Giordano, and E Frati, and M L Castagna, and G Morozzi, and M Lalumera, and R Marcolongo
September 1973, Experientia,
Copied contents to your clipboard!